NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020.

Mycosis fungoides (MF) is the most common subtype of cutaneous T-cell lymphoma (CTCL), and Sézary syndrome (SS) is a rare erythrodermic and leukemic subtype of CTCL characterized by significant blood involvement. Although early-stage disease can be effectively treated predominantly with skin-directed therapies, systemic therapy is often necessary for the treatment of advanced-stage disease. Systemic therapy options have evolved in recent years with the approval of novel agents such as romidepsin, brentuximab vedotin, and mogamulizumab. These NCCN Guidelines Insights discuss the diagnosis and management of MF and SS (with a focus on systemic therapy).

[1]  T. Miyamoto,et al.  Outcome of allogeneic hematopoietic stem cell transplantation for mycosis fungoides and Sézary syndrome , 2020, Hematological oncology.

[2]  H. Kohrt,et al.  Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  H. Tun,et al.  Efficacy of allogeneic hematopoietic cell transplantation in cutaneous T-cell lymphoma: results of a systematic review/meta-analysis. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[4]  E. Jaffe,et al.  The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. , 2019, Blood.

[5]  C. Elmets,et al.  Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. , 2018, The Lancet. Oncology.

[6]  R. Clark,et al.  High-throughput sequencing of the T cell receptor β gene identifies aggressive early-stage mycosis fungoides , 2018, Science Translational Medicine.

[7]  J. Scarisbrick,et al.  The Results of Low-Dose Total Skin Electron Beam Radiation Therapy (TSEB) in Patients With Mycosis Fungoides From the UK Cutaneous Lymphoma Group. , 2017, International journal of radiation oncology, biology, physics.

[8]  J. Scarisbrick,et al.  Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  L. Wilson,et al.  Annual Facility Treatment Volume and Patient Survival for Mycosis Fungoides and Sézary Syndrome , 2017, Clinical lymphoma, myeloma & leukemia.

[10]  M. Duvic,et al.  Clinical characteristics, risk factors and long-term outcome of 114 patients with folliculotropic mycosis fungoides , 2017, Archives of Dermatological Research.

[11]  J. Cerhan,et al.  2016 US lymphoid malignancy statistics by World Health Organization subtypes , 2016, CA: a cancer journal for clinicians.

[12]  R. Willemze,et al.  Clinical Staging and Prognostic Factors in Folliculotropic Mycosis Fungoides. , 2016, JAMA dermatology.

[13]  M. Feinmesser,et al.  New insights into folliculotropic mycosis fungoides (FMF): A single-center experience. , 2016, Journal of the American Academy of Dermatology.

[14]  H. Shimizu,et al.  Allogeneic hematopoietic stem cell transplantation following reduced‐intensity conditioning for mycosis fungoides and Sezary syndrome , 2016, Hematological oncology.

[15]  Y. Oki,et al.  Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  H. Eich,et al.  Total Skin Electron Beam for Primary Cutaneous T-cell Lymphoma. , 2015, International journal of radiation oncology, biology, physics.

[17]  Rei Watanabe,et al.  TCR sequencing facilitates diagnosis and identifies mature T cells as the cell of origin in CTCL , 2015, Science Translational Medicine.

[18]  R. Cowan,et al.  Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M. Tetzlaff,et al.  Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  R. Advani,et al.  Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  D. Schatz,et al.  Genomic landscape of cutaneous T cell lymphoma , 2015, Nature Genetics.

[22]  J. Becker,et al.  Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma , 2015, Leukemia & lymphoma.

[23]  L. Specht,et al.  Low-dose (10-Gy) total skin electron beam therapy for cutaneous T-cell lymphoma: an open clinical study and pooled data analysis. , 2015, International journal of radiation oncology, biology, physics.

[24]  R. Hoppe,et al.  Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: results of a pooled analysis from 3 phase-II clinical trials. , 2015, Journal of the American Academy of Dermatology.

[25]  N. Schmitz,et al.  Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a European society for blood and marrow transplantation lymphoma working party extended analysis. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  M. Duvic,et al.  Pralatrexate alone or in combination with bexarotene: long-term tolerability in relapsed/refractory mycosis fungoides. , 2014, Clinical lymphoma, myeloma & leukemia.

[27]  Alan M. Miller,et al.  ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR MYCOSIS FUNGOIDES AND SEZARY SYNDROME , 2014, Bone Marrow Transplantation.

[28]  P. Zinzani,et al.  Long-term outcome of patients with advanced-stage cutaneous T cell lymphoma treated with gemcitabine , 2014, Annals of Hematology.

[29]  O. Dereure,et al.  Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas , 2014, Haematologica.

[30]  J. Cayuela,et al.  Long‐term efficacy and safety of alemtuzumab in advanced primary cutaneous T‐cell lymphomas , 2014, The British journal of dermatology.

[31]  A. Enk,et al.  Guidelines on the use of extracorporeal photopheresis , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

[32]  Paola Savoia,et al.  Extracorporeal photopheresis for the treatment of erythrodermic cutaneous T‐cell lymphoma: a single center clinical experience with long‐term follow‐up data and a brief overview of the literature , 2013, International journal of dermatology.

[33]  M. Weichenthal,et al.  Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  R. Dummer,et al.  Efficacy and safety of bexarotene combined with psoralen–ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB–IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial 21011 (NCT00056056) , 2012, The British journal of dermatology.

[35]  B. Coiffier,et al.  Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study. , 2012, Clinical lymphoma, myeloma & leukemia.

[36]  Wei Wei,et al.  Long-term Outcomes of 1,263 Patients with Mycosis Fungoides and Sézary Syndrome from 1982 to 2009 , 2012, Clinical Cancer Research.

[37]  D. Fisher,et al.  Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. , 2012, Blood.

[38]  M. Siakantaris,et al.  Management of cutaneous T-Cell lymphoma patients with extracorporeal photopheresis. The Hellenic experience. , 2012, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[39]  R. Advani,et al.  Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). , 2011, Journal of the American Academy of Dermatology.

[40]  J. Scarisbrick,et al.  Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  J. Becker,et al.  Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  James J. Campbell,et al.  Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. , 2010, Blood.

[43]  A. Weaver,et al.  Folliculotropic mycosis fungoides: single-center study and systematic review. , 2010, Archives of dermatology.

[44]  Andrew H. Beck,et al.  Combined use of PCR-based TCRG and TCRB clonality tests on paraffin-embedded skin tissue in the differential diagnosis of mycosis fungoides and inflammatory dermatoses. , 2010, The Journal of molecular diagnostics : JMD.

[45]  E. Olsen,et al.  Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma. , 2009, Clinical lymphoma & myeloma.

[46]  A. Rademaker,et al.  Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center , 2009, Leukemia & lymphoma.

[47]  S. Steinberg,et al.  Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  P. Morel,et al.  Gemcitabine treatment in cutaneous T‐cell lymphoma: a multicentre study of 23 cases , 2009, The British journal of dermatology.

[49]  S. Devesa,et al.  Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. , 2009, Blood.

[50]  S. Lade,et al.  Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation. , 2008, Blood.

[51]  R. Baiocchi,et al.  Subcutaneous alemtuzumab for Sézary Syndrome in the very elderly. , 2008, Leukemia research.

[52]  T. Kuzel,et al.  Folliculotropic mycosis fungoides: an aggressive variant of cutaneous T-cell lymphoma. , 2008, Archives of dermatology.

[53]  B. Dréno,et al.  Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sézary syndrome. , 2008, Archives of dermatology.

[54]  N. Schmitz,et al.  Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma , 2008, Bone Marrow Transplantation.

[55]  J. Zehnder,et al.  T-cell clonality analysis in biopsy specimens from two different skin sites shows high specificity in the diagnosis of patients with suggested mycosis fungoides. , 2007, Journal of the American Academy of Dermatology.

[56]  Nicola Pimpinelli,et al.  Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). , 2007, Blood.

[57]  T. Kuzel,et al.  Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  P. Quaglino,et al.  Low-dose intermittent alemtuzumab in the treatment of Sézary syndrome: clinical and immunologic findings in 14 patients. , 2007, Haematologica.

[59]  N. Pimpinelli,et al.  Pegylated liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphomas. , 2007, Haematologica.

[60]  T. Kuzel,et al.  Results of a Phase II trial of oral bexarotene (Targretin) combined with interferon alfa‐2b (Intron‐A) for patients with cutaneous T‐cell lymphoma , 2007, Cancer.

[61]  R. Kurzrock,et al.  Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. , 2006, Clinical lymphoma & myeloma.

[62]  Nicola Pimpinelli,et al.  Defining early mycosis fungoides. , 2005, Journal of the American Academy of Dermatology.

[63]  E. Olsen.  Interferon in the treatment of cutaneous T‐cell lymphoma , 2003, Hematology/oncology clinics of North America.

[64]  M. Kashani-Sabet,et al.  Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients. , 2003, Journal of the American Academy of Dermatology.

[65]  Terry L. Smith,et al.  Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma. , 2003, Journal of the American Academy of Dermatology.

[66]  M. Baccarani,et al.  Clinical Observations, Interventions, and Therapeutic Trials , 2000 .

[67]  R. Willemze,et al.  Follicular mycosis fungoides, a distinct disease entity with or without associated follicular mucinosis: a clinicopathologic and follow-up study of 51 patients. , 2002, Archives of dermatology.

[68]  G. Wood,et al.  Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. , 2001, Archives of dermatology.

[69]  M. Duvic,et al.  Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  S. Pileri,et al.  Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  T. Petrella,et al.  Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneious Lymphomas. , 2000, Blood.

[72]  R. Kurzrock,et al.  Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis. , 1998, Blood.

[73]  P. Bunn,et al.  Phase II study of recombinant human interferon gamma for treatment of cutaneous T-cell lymphoma. , 1990, Journal of the National Cancer Institute.

[74]  S. Lade,et al.  Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy. , 2015, Blood.

[75]  Chunlei Zhang,et al.  Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). , 2007, Blood.